BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation

Overview of attention for article published in Molecular Cancer Research, December 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (77th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

So far, Altmetric has seen 10 tweets from 8 users, with an upper bound of 14,919 followers.

BET Inhibitors Target the SCLC-N Subtype of #SmallCellLungCancer by Blocking #NEUROD1 Transactivation, by Chen et al. https://t.co/zNVVwqzUva @NIHClinicalCntr https://t.co/pQk84jdkXg

RT @Tony_Calles: 💥 Fascinating: targeting transcriptional coactivators to regulate master transcription factors in SCLC. 💊 BET Inhibitors…

RT @MCR_AACR: Chen et al. show that BET proteins regulate NEUROD1 transactivation, making #BETinhibitors potentially attractive therapeutic…

RT @MCR_AACR: Chen et al. show that BET proteins regulate NEUROD1 transactivation, making #BETinhibitors potentially attractive therapeutic…

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity, including 6 additional tweets.